




Instance: composition-en-0dd5f884d9dc5fa6d9fea8dd6125a60a
InstanceOf: CompositionUvEpi
Title: "Composition for sitagliptin Package Leaflet"
Description:  "Composition for sitagliptin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp0dd5f884d9dc5fa6d9fea8dd6125a60a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sitagliptin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Sitagliptin SUN is and what it is used for </li>
<li>What you need to know before you take Sitagliptin SUN </li>
<li>How to take Sitagliptin SUN </li>
<li>Possible side effects </li>
<li>How to store Sitagliptin SUN </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sitagliptin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sitagliptin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sitagliptin SUN contains the active substance sitagliptin which is a member of a class of medicines 
called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in adult 
patients with type 2 diabetes mellitus. </p>
<p>This medicine helps to increase the levels of insulin produced after a meal and decreases the amount of 
sugar made by the body. </p>
<p>Your doctor has prescribed this medicine to help lower your blood sugar, which is too high because of 
your type 2 diabetes. This medicine can be used alone or in combination with certain other medicines 
(insulin, metformin, sulphonylureas, or glitazones) that lower blood sugar, which you may already be 
taking for your diabetes together with a food and exercise plan. </p>
<p>What is type 2 diabetes? 
Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that 
your body produces does not work as well as it should. Your body can also make too much sugar. 
When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems 
like heart disease, kidney disease, blindness, and amputation. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sitagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sitagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Sitagliptin SUN 
- if you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 
6). </p>
<p>Warnings and precautions 
Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving 
sitagliptin (see section 4). 
If you encounter blistering of the skin it may be a sign for a condition called bullous pemphigoid. 
Your doctor may ask you to stop Sitagliptin SUN. </p>
<p>Tell your doctor if you have or have had:</p>
<ul>
<li>a disease of the pancreas (such as pancreatitis) </li>
<li>gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood. 
These medical conditions can increase your chance of getting pancreatitis (see section 4). </li>
<li>type 1 diabetes </li>
<li>diabetic ketoacidosis (a complication of diabetes with high blood sugar, rapid weight loss, 
nausea or vomiting) </li>
<li>any past or present kidney problems </li>
<li>an allergic reaction to sitagliptin (see section 4) </li>
</ul>
<p>This medicine is unlikely to cause low blood sugar because it does not work when your blood sugar is 
low. However, when this medicine is used in combination with a sulphonylurea medicine or with 
insulin, low blood sugar (hypoglycaemia) can occur. Your doctor may reduce the dose of your 
sulphonylurea or insulin medicine. </p>
<p>Children and adolescents 
Children and adolescents below 18 years should not use this medicine. It is not effective in children 
and adolescents between the ages of 10 and 17 years. It is not known if this medicine is safe and 
effective when used in children younger than 10 years. </p>
<p>Other medicines and Sitagliptin SUN 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>In particular, tell your doctor if you are taking digoxin (a medicine used to treat irregular heartbeat and 
other heart problems). The level of digoxin in your blood may need to be checked if taking with 
sitagliptin. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. 
You should not take this medicine during pregnancy. </p>
<p>It is not known if this medicine passes into breast milk. You should not take this medicine if you are 
breast-feeding or plan to breast-feed. </p>
<p>Driving and using machines 
This medicine has no or negligible influence on the ability to drive and use machines. However, 
dizziness and drowsiness have been reported, which may affect your ability to drive or use machines. </p>
<p>Taking this medicine in combination with medicines called sulphonylureas or with insulin can cause 
hypoglycaemia, which may affect your ability to drive and use machines or work without safe 
foothold. </p>
<p>Sitagliptin SUN contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free . </p>
<p>Sitagliptin SUN contains hydrogenated castor oil<br />
May cause stomach upset and diarrhea. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sitagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sitagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>The usual recommended dose is: </p>
<p>one 100 mg film-coated tablet </p>
<p>once a day </p>
<p>by mouth </p>
<p>If you have kidney problems, your doctor may prescribe lower doses (such as 25 mg or 50 mg).  </p>
<p>You can take this medicine with or without food. </p>
<p>Your doctor may prescribe this medicine alone or with certain other medicines that lower blood sugar. </p>
<p>Diet and exercise can help your body use its blood sugar better. It is important to stay on the diet and 
exercise recommended by your doctor while taking sitagliptin. </p>
<p>If you take more Sitagliptin SUN than you should 
If you take more than the prescribed dose of this medicine, contact your doctor immediately. </p>
<p>If you forget to take Sitagliptin SUN 
If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your 
next dose, skip the missed dose and go back to your regular schedule. Do not take a double dose of 
this medicine. </p>
<p>If you stop taking Sitagliptin SUN 
Continue to take this medicine as long as your doctor prescribes it so you can continue to help control 
your blood sugar. You should not stop taking this medicine without talking to your doctor first. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>STOP taking sitagliptin and contact a doctor immediately if you notice any of the following serious 
side effects:</p>
<ul>
<li>Severe and persistent pain in the abdomen (stomach area) which might reach through to your 
back with or without nausea and vomiting, as these could be signs of an inflamed pancreas 
(pancreatitis). </li>
</ul>
<p>If you have a serious allergic reaction (frequency not known), including rash, hives, blisters on the 
skin/peeling skin and swelling of the face, lips, tongue, and throat that may cause difficulty in 
breathing or swallowing, stop taking this medicine and call your doctor right away. Your doctor may 
prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes. </p>
<p>Some patients have experienced the following side effects after adding sitagliptin to metformin: 
Common (may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting 
Uncommon (may affect up to 1 in 100 people): stomach ache, diarrhoea, constipation, drowsiness </p>
<p>Some patients have experienced different types of stomach discomfort when starting the combination 
of sitagliptin and metformin together (frequency is common). </p>
<p>Some patients have experienced the following side effects while taking sitagliptin in combination with 
a sulphonylurea and metformin: 
Very common (may affect more than 1 in 10 people): low blood sugar<br />
Common: constipation </p>
<p>Some patients have experienced the following side effects while taking sitagliptin and pioglitazone: 
Common: flatulence, swelling of the hands or legs </p>
<p>Some patients have experienced the following side effects while taking sitagliptin in combination with 
pioglitazone and metformin: 
Common: swelling of the hands or legs </p>
<p>Some patients have experienced the following side effects while taking sitagliptin in combination with 
insulin (with or without metformin): 
Common: flu<br />
Uncommon: dry mouth </p>
<p>Some patients have experienced the following side effects while taking sitagliptin alone in clinical 
studies, or during post-approval use alone and/or with other diabetes medicines: 
Common: low blood sugar, headache, upper respiratory infection, stuffy or runny nose and sore throat, 
osteoarthritis, arm or leg pain 
Uncommon: dizziness, constipation, itching<br />
Rare: reduced number of platelets 
Frequency not known: kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle 
pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sitagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sitagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and the carton after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw 
away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Sitagliptin SUN contains 
- The active substance is sitagliptin: * 
Each Sitagliptin SUN 25 mg film-coated tablet contains sitagliptin fumarate, equivalent 
to 25 mg sitagliptin. * 
Each Sitagliptin SUN 50 mg film-coated tablet contains sitagliptin fumarate, equivalent 
to 50 mg sitagliptin. * 
Each Sitagliptin SUN 100 mg film-coated tablet contains sitagliptin fumarate, equivalent 
to 100 mg sitagliptin. </p>
<ul>
<li>The other ingredients are:  * 
Tablet core: calcium hydrogen phosphate (E341), crospovidone type A (E1202), 
hydrogenated castor oil, glycerol dibehenate, and magnesium stearate (E470b).  * 
Film-coating: hypromellose 2910/5 (E464), titanium dioxide (E171), macrogol 6(E1521), talc (E553b), red iron oxide (E172), and yellow iron oxide (E172). </li>
</ul>
<p>What Sitagliptin SUN looks like and contents of the pack 
- Sitagliptin SUN 25 mg film-coated tablets: Light pink colour, round film-coated tablets, 
dimensions approximately 6 mm x 3 mm, debossed with F1 on one side and plain on the other 
side. 
- Sitagliptin SUN 50 mg film-coated tablets: Light beige colour, round film-coated tablets, 
dimensions approximately 8 mm x 4 mm, debossed with F2 on one side and plain on the other 
side. 
- Sitagliptin SUN 100 mg film-coated tablets: Beige colour, round film-coated tablets, 
dimensions approximately 10 mm x 4.5 mm, debossed with F3 on one side and plain on the 
other side. </p>
<p>Sitagliptin SUN film-coated tablets are packed in PA/Alu/PE + desiccant/HDPE/Alu blisters. They are 
available in pack sizes of 28, 56 or 98 film-coated tablets.  </p>
<p>Sitagliptin SUN film-coated tablets are also available in packs containing one HDPE bottle of 
90 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
Sun Pharmaceutical Industries Europe B.V.<br />
Polarisavenue 2132JH Hoofddorp 
The Netherlands </p>
<p>Manufacturer 
Sun Pharmaceutical Industries Europe B.V.<br />
Polarisavenue 2132JH Hoofddorp 
The Netherlands </p>
<p>Terapia S.A. 
Str. Fabricii nr. Cluj-Napoca, 400Romania </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien/ / esk  republika/ 
Danmark/Eesti/ /Hrvatska/Ireland/ sland/ 
 /Latvija/Lietuva/Luxembourg/Luxemburg/Magyarorsz g/ 
Malta/Nederland/Norge/ sterreich/Portugal/ 
Slovenija/Slovensk  republika/Suomi/Finland/Sverige 
Sun Pharmaceutical Industries Europe B.V. 
Polarisavenue 2132 JH Hoofddorp 
Nederland/Pays-Bas/Niederlande/ /Nizozemsko/ 
Nederlandene/Holland/ /Nizozemska/The Netherlands/Holland/ 
 /N derlande/Nyderlandai/Pays-Bas/Niederlande/Hollandia/ 
L-Olanda/Nederland/Nederland/Niederlande/Pa ses Baixos/ 
Nizozemska/Holandsko/Alankomaat/Nederl nderna/Nederl nderna 
Tel./ ./tlf./ ./S mi/ ./Tlf./Puh./ 
 +31 (0)23 568 5Deutschland 
Sun Pharmaceuticals Germany GmbH 
Hemmelrather Weg 51377 Leverkusen 
Deutschland 
Tel. +49 (0) 214 40399 0 </p>
<p>Espa a 
Sun Pharma Laboratorios, S.L.<br />
Rambla de Catalunya 53-08007 Barcelona 
Espa a 
tel. +34 93 342 78 France 
Sun Pharma France 
11-15, Quai de Dion Bouton 
92800 Puteaux 
France 
Tel. +33 1 41 44 44 Italia 
Sun Pharma Italia Srl 
Viale Giulio Richard, 1 
20143 Milano 
Italia 
tel. +39 02 33 49 07 Polska 
Ranbaxy (Poland) Sp. Z o. o. 
ul. Kubickiego 02-954 Warszawa<br />
Polska 
Tel. +48 22 642 07 Rom nia 
Terapia S.A. 
Str. Fabricii nr Cluj-Napoca, Jude ul Cluj 
Rom nia 
Tel. +40 (264) 501 United Kingdom (Northern Ireland) 
Sun Pharma UK Limited 
6-9 The Square 
Stockley Park 
Uxbridge 
UB11 1FW 
United Kingdom 
Tel. +44 (0) 208 848 8This leaflet was last revised in                    . </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-0dd5f884d9dc5fa6d9fea8dd6125a60a
InstanceOf: CompositionUvEpi
Title: "Composition for sitagliptin Package Leaflet"
Description:  "Composition for sitagliptin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp0dd5f884d9dc5fa6d9fea8dd6125a60a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sitagliptin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at tage Sitagliptin SUN 
3. Sådan skal De tage Sitagliptin SUN 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sitagliptin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sitagliptin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sitagliptin SUN indeholder det aktive stof sitagliptin, som tilhører en klasse af lægemidler, som kaldes 
DPP-4- hæmmere (dipeptylpeptidase-4-hæmmere). Disse lægemidler sænker blodsukkeret hos voksne 
patienter med type 2-diabetes mellitus. Dette lægemiddel hjælper med at øge mængden af insulin, der 
frigives efter et måltid, og nedsætter mængden af sukker, der dannes af kroppen. </p>
<p>Deres læge har foreskrevet dette lægemiddel som en hjælp til at sænke Deres blodsukker, som er for 
højt på grund af Deres type 2-diabetes. Lægemidlet kan bruges alene eller sammen med visse andre 
lægemidler (insulin, metformin, sulfonylurinstof eller glitazoner), som sænker blodsukkeret, og som 
De måske allerede tager for Deres diabetes, samtidig med at De følger en diæt- og motionsplan. </p>
<p>Hvad er type 2-diabetes? 
Type 2-diabetes er en tilstand, hvor Deres krop ikke danner nok insulin, samtidig med at det insulin, 
som Deres krop danner, ikke virker så godt, som det burde. Deres krop kan også danne for meget 
sukker. Når dette sker, øges sukkerindholdet (glucose) i blodet. Dette kan føre til alvorlige 
helbredsproblemer som hjertesygdom, nyresygdom, blindhed og amputation. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sitagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sitagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Sitagliptin SUN 
- hvis De er allergisk over for sitagliptin eller et af de øvrige indholdsstoffer i lægemidlet (angivet 
i punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Der er indberettet tilfælde af betændelse i bugspytkirtlen (pankreatitis) hos patienter, der får sitagliptin 
(se punkt 4). </p>
<p>Hvis De får blærer på huden, kan det være et tegn på en hudsygdom kaldet bulløs pemfigoid. Lægen 
vil måske bede Dem om at stoppe med at tage Sitagliptin SUN. </p>
<p>Fortæl Deres læge, om De har eller har haft:</p>
<ul>
<li>En sygdom i bugspytkirtlen (f.eks. pankreatitis). </li>
<li>Galdesten, alkoholafhængighed eller et meget højt indhold af triglycerider (en fedtstoftype) i 
blodet. Disse sygdomme kan forøge risikoen for at få pankreatitis (se punkt 4). </li>
<li>Type 1-diabetes. </li>
<li>Komplikation til diabetes med forhøjet blodsukker, hurtigt vægttab, kvalme eller opkastning 
(diabetisk ketoacidose). </li>
<li>Tidligere eller nuværende nyreproblemer. </li>
<li>Allergisk reaktion over for sitagliptin (se punkt 4). </li>
</ul>
<p>Dette lægemiddel vil ikke forårsage lavt blodsukker, fordi det ikke virker, når Deres blodsukker er lavt. 
Når lægemidlet tages sammen med et sulfonylurinstof eller sammen med insulin, kan lavt blodsukker 
(hypoglykæmi) forekomme. 
Lægen vil måske nedsætte dosis af sulfonylurinstof eller insulin. </p>
<p>Børn og unge 
Dette lægemiddel må ikke anvendes til børn og unge under 18 år. Det er ikke effektivt hos børn og 
unge i alderen 10 til 17 år. Det er ukendt, om dette lægemiddel er sikkert og effektivt, når det anvendes 
hos børn under 10 år. </p>
<p>Brug af anden medicin sammen med Sitagliptin SUN 
Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger anden medicin, for nylig har brugt 
anden medicin eller planlægger at bruge anden medicin. </p>
<p>Fortæl det især til lægen, hvis De tager digoxin (et lægemiddel til behandling af uregelmæssig 
hjerterytme og andre hjerteproblemer). Det kan være nødvendigt at kontrollere indholdet af digoxin i 
Deres blod, hvis De tager sitagliptin. </p>
<p>Graviditet og amning 
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel. De bør ikke tage 
dette lægemiddel under graviditet. </p>
<p>Det vides ikke, om lægemidlet går over i mælken. De bør ikke tage dette lægemiddel, hvis De ammer 
eller planlægger at amme. </p>
<p>Trafik- og arbejdssikkerhed 
Lægemidlet påvirker ikke eller kun i ubetydelig grad evnen til at køre bil eller betjene maskiner. Der 
har dog været rapporter om svimmelhed og døsighed, hvilket kan påvirke Deres evne til at køre bil 
eller betjene maskiner. </p>
<p>Hvis De tager dette lægemiddel sammen med medicin, der kaldes sulfonylurinstof eller sammen med 
insulin, kan det medføre for lavt blodsukker (hypoglykæmi), som kan påvirke Deres evne til at køre bil 
og betjene maskiner, eller hvis De arbejder uden sikkert fodfæste. </p>
<p>Sitagliptin SUN indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>
<p>Sitagliptin SUN indeholder hydrogeneret ricinusolie 
Kan forårsage mavebesvær og diarré. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sitagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sitagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Den almindelige anbefalede dosis er:</p>
<ul>
<li>En 100 mg filmovertrukken tablet. </li>
<li>En gang dagligt. </li>
<li>Gennem munden. </li>
</ul>
<p>Hvis De har nyreproblemer, kan Deres læge ordinere en lavere dosis (såsom 25 mg eller 50 mg).   </p>
<p>De kan tage dette lægemiddel med eller uden mad. </p>
<p>Deres læge kan ordinere dette lægemiddel alene eller sammen med visse andre lægemidler, der sænker 
blodsukkeret. </p>
<p>Diæt og motion kan hjælpe Dem, så kroppen bruger sit blodsukker bedre. Det er vigtigt at forblive på 
den diæt og motion, som lægen anbefaler, mens De tager sitagliptin. </p>
<p>Hvis De har taget for meget Sitagliptin SUN 
Kontakt straks Deres læge, hvis De har taget mere end den foreskrevne dosis af dette lægemiddel. </p>
<p>Hvis De har glemt at tage Sitagliptin SUN 
Hvis De glemmer en dosis, så tag den, så snart De kommer i tanke om det. Hvis De ikke kommer i 
tanke om det, før det er tid til næste dosis, skal De springe den glemte dosis over og tage den næste 
dosis som normalt. De må ikke tage en dobbeltdosis som erstatning for den glemte dosis af 
lægemidlet. </p>
<p>Hvis De holder op med at tage Sitagliptin SUN 
Fortsæt med at tage Sitagliptin SUN, så længe Deres læge ordinerer det, så De fortsat kan få hjælp til 
at kontrollere Deres blodsukker. De bør ikke holde op med at tage dette lægemiddel uden at tale med 
lægen først. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>STOP med at tage sitagliptin og kontakt straks lægen, hvis De får nogen af følgende alvorlige 
bivirkninger:</p>
<ul>
<li>Svære og vedvarende smerter i maven, som kan stråle ud i ryggen, med eller uden kvalme og 
opkastning, da det kan være tegn på betændelse i bugspytkirtlen (pankreatitis). </li>
</ul>
<p>Hvis De får en alvorlig allergisk reaktion (hyppighed ikke kendt), herunder udslæt, nældefeber, blærer 
på huden/hudafskalning og hævelse af ansigt, læber, tunge og svælg, som kan medføre vejrtræknings- og synkebesvær, skal De stoppe med at tage dette lægemiddel og kontakte lægen omgående. Lægen 
kan ordinere et lægemiddel til behandling af Deres allergiske reaktion og et andet lægemiddel til 
Deres diabetes. </p>
<p>Nogle patienter har oplevet følgende bivirkninger, efter at sitagliptin er blevet føjet til metformin: 
Almindelige (kan berøre op til 1 ud af 10): Lavt blodsukker, kvalme, øget luftafgang fra tarmen, 
opkastning. 
Ikke almindelige (kan berøre op til 1 ud af 100): Mavesmerter, diarré, forstoppelse, døsighed. </p>
<p>Nogle patienter har oplevet forskellige typer mavegener, når de er startet med at kombinere sitagliptin 
og metformin (hyppighed: almindelig). </p>
<p>Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin sammen med et </p>
<p>sulfonylurinstof og metformin: 
Meget almindelig (kan berøre flere end 1 ud af 10): Lavt blodsukker.<br />
Almindelig: Forstoppelse. </p>
<p>Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin og pioglitazon: 
Almindelige: Øget luftafgang fra tarmen, hævede hænder eller ben. </p>
<p>Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin sammen med pioglitazon 
og metformin: 
Almindelige: Hævede hænder eller ben. </p>
<p>Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin sammen med insulin 
(med eller uden metformin): 
Almindelig: Influenza.<br />
Ikke almindelig: Tør mund. </p>
<p>Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin alene i kliniske studier 
eller ved anvendelse efter markedsføring alene og/eller sammen med anden diabetesmedicin: 
Almindelige: Lavt blodsukker, hovedpine, infektion i øvre luftveje, stoppet næse eller snue og ondt i 
halsen, betændelse i led og den tilgrænsende knogle, smerter i arme eller ben. 
Ikke almindelige: Svimmelhed, forstoppelse, kløe.<br />
Sjælden: Nedsat antal blodplader. 
Hyppighed ikke kendt: Nyreproblemer (som kan kræve dialyse), opkastning, ledsmerter, 
muskelsmerter, rygsmerter, interstitiel lungesygdom, bulløs pemfigoid (en type blærer på huden). </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge, apotekspersonalet eller sygeplejersken. 
Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres 
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale 
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at 
fremskaffe mere information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sitagliptin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sitagliptin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisteren og kartonen efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Denne medicin kræver ikke særlige opbevaringsforhold. </p>
<p>Spørg apotekspersonalet, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sitagliptin SUN indeholder:</p>
<ul>
<li>
<p>Aktivt stof: sitagliptin: * 
Hver Sitagliptin SUN 25 mg filmovertrukken tablet indeholder sitagliptin fumarat, der 
svarer til 25 mg sitagliptin. * 
Hver Sitagliptin SUN 50 mg filmovertrukken tablet indeholder sitagliptin fumarat, der 
svarer til 50 mg sitagliptin. * 
Hver Sitagliptin SUN 100 mg filmovertrukken tablet indeholder sitagliptin fumarat, der 
svarer til 100 mg sitagliptin. </p>
</li>
<li>
<p>Øvrige indholdsstoffer:  * 
Tabletkerne: Calciumhydrogenphosphat (E341), crospovidon type A (E1202), 
hydrogeneret ricinusolie, glycerol-dibehenat, magnesiumstearat (E470b).  * 
Filmovertræk: Hypromellose 2910/5 (E464), titandioxid (E171), macrogol 6000 (E1521), 
talcum (E553b), rød jernoxid (E172), gul jernoxid (E172). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
- Sitagliptin SUN 25 mg filmovertrukne tabletter: Lyserøde, runde filmovertrukne tabletter, 
dimensioner ca. 6 mm x 3 mm, præget med F1 på den ene side og glat på den anden side. 
- Sitagliptin SUN 50 mg filmovertrukne tabletter: Lysbeige, runde filmovertrukne tabletter, 
dimensioner ca. 8 mm x 4 mm, præget med F2 på den ene side og glat på den anden side. 
- Sitagliptin SUN 100 mg filmovertrukne tabletter: Beige, runde filmovertrukne tabletter, 
dimensioner ca. 10 mm x 4,5 mm, præget med F3 på den ene side og glat på den anden side. </p>
<p>Sitagliptin SUN filmovertrukne tabletter er pakket i PA/Alu/PE + tørremiddel/HDPE/Al 
blisterpakninger. De fås i pakningsstørrelser med 28, 56 eller 98 filmovertrukne tabletter. </p>
<p>Sitagliptin SUN filmovertrukne tabletter fås også i pakninger indeholdende en HDPE-flaske med filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen<br />
Sun Pharmaceutical Industries Europe B.V.<br />
Polarisavenue 2132JH Hoofddorp 
Holland </p>
<p>Fremstiller 
Sun Pharmaceutical Industries Europe B.V.<br />
Polarisavenue 2132JH Hoofddorp 
Holland </p>
<p>Terapia S.A. 
Str. Fabricii nr. Cluj-Napoca, 400Rumænien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien/България/Česká republika/ 
Danmark/Eesti/Ελλάδα/Hrvatska/Ireland/Ísland/ 
Κύπρος/Latvija/Lietuva/Luxembourg/Luxemburg/Magyarország/ 
Malta/Nederland/Norge/Österreich/Portugal/ 
Slovenija/Slovenská republika/Suomi/Finland/Sverige 
Sun Pharmaceutical Industries Europe B.V. 
Polarisavenue 2132 JH Hoofddorp 
Nederland/Pays-Bas/Niederlande/Нидерландия/Nizozemsko/ 
Nederlandene/Holland/Ολλανδία/Nizozemska/The Netherlands/Holland/ 
Ολλανδία/Nīderlande/Nyderlandai/Pays-Bas/Niederlande/Hollandia/ 
L-Olanda/Nederland/Nederland/Niederlande/Países Baixos/ 
Nizozemska/Holandsko/Alankomaat/Nederländerna/Nederländerna 
Tel./тел./tlf./τηλ./Sími/τηλ./Tlf./Puh./ 
 +31 (0)23 568 5 </p>
<p>Deutschland 
Sun Pharmaceuticals Germany GmbH 
Hemmelrather Weg 51377 Leverkusen 
Deutschland 
Tel. +49 (0) 214 40399 0 </p>
<p>España 
Sun Pharma Laboratorios, S.L.<br />
Rambla de Catalunya 53-08007 Barcelona 
España 
tel. +34 93 342 78<br />
France 
Sun Pharma France 
11-15, Quai de Dion Bouton 
92800 Puteaux 
France 
Tel. +33 1 41 44 44<br />
Italia 
Sun Pharma Italia Srl 
Viale Giulio Richard, 1 
20143 Milano 
Italia 
tel. +39 02 33 49 07<br />
Polska 
Ranbaxy (Poland) Sp. Z o. o. 
ul. Kubickiego 11<br />
02-954 Warszawa<br />
Polska 
Tel. +48 22 642 07<br />
România 
Terapia S.A. 
Str. Fabricii nr Cluj-Napoca, Judeţul Cluj 
România 
Tel. +40 (264) 501<br />
United Kingdom (Northern Ireland) 
Sun Pharma UK Limited 
6-9 The Square,<br />
Stockley Park, 
Uxbridge 
UB11 1FW 
United Kingdom 
Tel. +44 (0) 208 848 8 
Denne indlægsseddel blev senest ændret                            . </p>
<p>De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-0dd5f884d9dc5fa6d9fea8dd6125a60a
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sitagliptin Package Leaflet for language en"
Description: "ePI document Bundle for sitagliptin Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-0dd5f884d9dc5fa6d9fea8dd6125a60a"
* entry[0].resource = composition-en-0dd5f884d9dc5fa6d9fea8dd6125a60a

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp0dd5f884d9dc5fa6d9fea8dd6125a60a"
* entry[=].resource = mp0dd5f884d9dc5fa6d9fea8dd6125a60a
                            
                    
Instance: bundlepackageleaflet-da-0dd5f884d9dc5fa6d9fea8dd6125a60a
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sitagliptin Package Leaflet for language da"
Description: "ePI document Bundle for sitagliptin Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-0dd5f884d9dc5fa6d9fea8dd6125a60a"
* entry[0].resource = composition-da-0dd5f884d9dc5fa6d9fea8dd6125a60a

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp0dd5f884d9dc5fa6d9fea8dd6125a60a"
* entry[=].resource = mp0dd5f884d9dc5fa6d9fea8dd6125a60a
                            
                    



Instance: mp0dd5f884d9dc5fa6d9fea8dd6125a60a
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Sitagliptin SUN 25 mg film-coated tablets"
Description: "Sitagliptin SUN 25 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Sitagliptin SUN 25 mg film-coated tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Sitagliptin SUN 25 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 0dd5f884d9dc5fa6d9fea8dd6125a60aListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "sitagliptin"

* status = #current
* mode = #working

* title = "List of all ePIs associated with sitagliptin"

* subject = Reference(mp0dd5f884d9dc5fa6d9fea8dd6125a60a)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#sitagliptin "sitagliptin"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-0dd5f884d9dc5fa6d9fea8dd6125a60a) // sitagliptin en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-0dd5f884d9dc5fa6d9fea8dd6125a60a) // sitagliptin da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-0dd5f884d9dc5fa6d9fea8dd6125a60a
InstanceOf: List

* insert 0dd5f884d9dc5fa6d9fea8dd6125a60aListRuleset
    